

Case Study

Raydiant Oximetry

CIF Investment: August 2023

In the 50+ years that fetal heart-rate monitoring has been used during labor and delivery, the rate of emergency C-sections has increased more than 5 fold, with no significant reduction in neonatal injury.

Imagine if there were a more accurate tool to monitor fetal oxygenation, dramatically reducing the rate of C-sections and their subsequent complications.

Raydiant Oximetry is developing Lumerah, a **non-invasive sensor that directly measures fetal oxygen levels during labor and delivery**. They aim to profoundly reduce the rising mortality and morbidity rates of mothers during and following childbirth.

20% of deliveries in the US are by unplanned C-Sections, with 40% higher rates for black and hispanic women

Fetal heart-rate monitors have a high rate of false positives for fetal hypoxia, leading to unnecessary C-Sections

Subsequent complications from C-sections increase the risk of maternal mortality

Milestones, Results and Recognition

- **FDA Breakthrough Status:** Lumerah assigned Breakthrough Status by FDA to fast track approval process
- **In Pre-Clinical Trials:** Lumerah shown to be 80% more accurate than fetal heart rate monitors in diagnosing fetal distress

Asset Milestones

Solution	Discovery	Research	Clinical Trials	Commercialization
Lumerah	✓	✓	In Progress	